Switching from Adalimumab Originator to Biosimilar in Patients with Hidradenitis Suppurativa Results in Losses of Response—Data from the German HS Registry HSBest

Since 2021, adalimumab biosimilar ABP 501 can be used alternatively to adalimumab originator (ADAO) in the treatment of hidradenitis suppurativa (HS). Effectiveness and safety data remain scarce. We investigated the impact of switching from ADAO to ABP 501 on disease severity and the occurrence of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Kirsten, Natalia, Ohm, Frenz, Gehrdau, Kathrin, Girbig, Gefion, Stephan, Brigitte, Ben-Anaya, Nesrine, Pinter, Andreas, Bechara, Falk G., Presser, Dagmar, Zouboulis, Christos C., Augustin, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605653/
https://www.ncbi.nlm.nih.gov/pubmed/36294953
http://dx.doi.org/10.3390/life12101518

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605653/
https://www.ncbi.nlm.nih.gov/pubmed/36294953
http://dx.doi.org/10.3390/life12101518

Ejemplares similares